Cargando…
Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients
Fatigue is a prevalent symptom experienced by individuals diagnosed with multiple sclerosis (MS), which greatly affects their daily activities and causes frustration and depression, thus affecting their lives and society. This can be prevented through the use of medicines such as L-carnitine and mod...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483915/ https://www.ncbi.nlm.nih.gov/pubmed/37692018 http://dx.doi.org/10.4103/JAPTR.JAPTR_225_23 |
_version_ | 1785102488883429376 |
---|---|
author | Al-Shammari, Ahmed Hamza Abbood, Zainab A. Lateef, Hayder F. |
author_facet | Al-Shammari, Ahmed Hamza Abbood, Zainab A. Lateef, Hayder F. |
author_sort | Al-Shammari, Ahmed Hamza |
collection | PubMed |
description | Fatigue is a prevalent symptom experienced by individuals diagnosed with multiple sclerosis (MS), which greatly affects their daily activities and causes frustration and depression, thus affecting their lives and society. This can be prevented through the use of medicines such as L-carnitine and modafinil. The study aimed to examine the effect of L-carnitine and modafinil on fatigue and which one is better for MS patients. This was a clinical trial. This clinical trial was conducted in cooperation between Al-Kut University College and an MS consultant at Al-Zahraa Teaching Hospital in addition to the private neurological clinic from October 1, 2022, to March 15, 2023. Forty participants were split into two groups; both of which were almost identical characteristics regarding age, disease duration, and degree of fatigue. Group I (n = 20): relapsing-remitting MS patients with fatigue received modafinil. Group II (n = 20): relapsing-remitting MS patients with fatigue received L-carnitine. Fatigue was evaluated according to the Modified Fatigue Impact Scale (MFIS). The statistical work was done in SPSS (IBM Corp., Chicago, IL, USA, version 24). P values were calculated by the t-test. Significant data have P = 0.05. After 2 months of treatment, the results show a significant decrease in MFIS in both groups with a higher reduction in patients who use L-carnitine. Both modafinil and L-carnitine show a significant influence on fatigue in MS patients, and these effects are more in L-carnitine. |
format | Online Article Text |
id | pubmed-10483915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-104839152023-09-08 Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients Al-Shammari, Ahmed Hamza Abbood, Zainab A. Lateef, Hayder F. J Adv Pharm Technol Res Original Article Fatigue is a prevalent symptom experienced by individuals diagnosed with multiple sclerosis (MS), which greatly affects their daily activities and causes frustration and depression, thus affecting their lives and society. This can be prevented through the use of medicines such as L-carnitine and modafinil. The study aimed to examine the effect of L-carnitine and modafinil on fatigue and which one is better for MS patients. This was a clinical trial. This clinical trial was conducted in cooperation between Al-Kut University College and an MS consultant at Al-Zahraa Teaching Hospital in addition to the private neurological clinic from October 1, 2022, to March 15, 2023. Forty participants were split into two groups; both of which were almost identical characteristics regarding age, disease duration, and degree of fatigue. Group I (n = 20): relapsing-remitting MS patients with fatigue received modafinil. Group II (n = 20): relapsing-remitting MS patients with fatigue received L-carnitine. Fatigue was evaluated according to the Modified Fatigue Impact Scale (MFIS). The statistical work was done in SPSS (IBM Corp., Chicago, IL, USA, version 24). P values were calculated by the t-test. Significant data have P = 0.05. After 2 months of treatment, the results show a significant decrease in MFIS in both groups with a higher reduction in patients who use L-carnitine. Both modafinil and L-carnitine show a significant influence on fatigue in MS patients, and these effects are more in L-carnitine. Wolters Kluwer - Medknow 2023 2023-07-28 /pmc/articles/PMC10483915/ /pubmed/37692018 http://dx.doi.org/10.4103/JAPTR.JAPTR_225_23 Text en Copyright: © 2023 Journal of Advanced Pharmaceutical Technology & Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Al-Shammari, Ahmed Hamza Abbood, Zainab A. Lateef, Hayder F. Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients |
title | Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients |
title_full | Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients |
title_fullStr | Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients |
title_full_unstemmed | Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients |
title_short | Assessing the impacts of L-carnitine and modafinil on fatigue in Iraqi multiple sclerosis patients |
title_sort | assessing the impacts of l-carnitine and modafinil on fatigue in iraqi multiple sclerosis patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483915/ https://www.ncbi.nlm.nih.gov/pubmed/37692018 http://dx.doi.org/10.4103/JAPTR.JAPTR_225_23 |
work_keys_str_mv | AT alshammariahmedhamza assessingtheimpactsoflcarnitineandmodafinilonfatigueiniraqimultiplesclerosispatients AT abboodzainaba assessingtheimpactsoflcarnitineandmodafinilonfatigueiniraqimultiplesclerosispatients AT lateefhayderf assessingtheimpactsoflcarnitineandmodafinilonfatigueiniraqimultiplesclerosispatients |